{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=8", "query": { "intervention": "Placebo 50 or 100 mg", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 281, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:34:31.995Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "dextrose", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 342, "start_date": "2021-06-18", "completion_date": "2027-12-18", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895358" }, { "nct_id": "NCT00529568", "title": "Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "eltrombopag", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 759, "start_date": "2007-10", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2013-11-05", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Arcadia", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00529568" }, { "nct_id": "NCT01604343", "title": "A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sirukumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1670, "start_date": "2012-08-15", "completion_date": "2016-12-06", "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 48, "location_summary": "Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 45 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01604343" }, { "nct_id": "NCT01133821", "title": "Acute Psychotherapy for Bipolar II Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bipolar Disorder", "Depression" ], "interventions": [ { "name": "IPSRT plus placebo (IPSRT-PLA)", "type": "DRUG" }, { "name": "IPSRT plus quetiapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Holly Swartz", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 92, "start_date": "2010-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01133821" }, { "nct_id": "NCT03379506", "title": "Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "EBR/GZR FDC Tablet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Grazoprevir Oral Granules", "type": "DRUG" }, { "name": "Elbasvir Oral Granules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 57, "start_date": "2018-01-25", "completion_date": "2020-07-23", "has_results": true, "last_update_posted_date": "2023-05-31", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 8, "location_summary": "San Francisco, California • Orlando, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03379506" }, { "nct_id": "NCT05348993", "title": "Single or Repeat Dose of G03-52-01 in Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy", "Botulinum Toxin" ], "interventions": [ { "name": "G03-52-01", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 622, "start_date": "2022-06-15", "completion_date": "2025-02-18", "has_results": true, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 15, "location_summary": "Mobile, Alabama • Tempe, Arizona • Fort Myers, Florida + 11 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "El Dorado", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05348993" }, { "nct_id": "NCT05180773", "title": "Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Peripartum Cardiomyopathy, Postpartum" ], "interventions": [ { "name": "Bromocriptine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Guideline Directed Medical Therapy for Heart Failure (GDMT)", "type": "DRUG" }, { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Second Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dennis M. McNamara, MD, MS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 250, "start_date": "2022-07-27", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05180773" }, { "nct_id": "NCT01052831", "title": "Naltrexone for Impulse Control Disorders in Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Impulse Control Disorder", "Parkinson Disease" ], "interventions": [ { "name": "Naltrexone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 50, "start_date": "2009-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-08-06", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01052831" }, { "nct_id": "NCT04493216", "title": "A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "FTC/TAF", "type": "DRUG" }, { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2020-11-18", "completion_date": "2023-05-29", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 9, "location_summary": "Los Angeles, California • Ft. Pierce, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Berkley", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493216" }, { "nct_id": "NCT01549964", "title": "Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glycemic Control" ], "interventions": [ { "name": "Fasiglifam (TAK-875)", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 916, "start_date": "2012-04", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-06-02", "last_synced_at": "2026-10-14T09:34:31.995Z", "location_count": 58, "location_summary": "Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01549964" } ] }